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he Wearable
ardioverter-Defibrillator
ifesaving Attire or “Fashion Faux Pas?”*
alph J. Verdino, MD
hiladelphia, Pennsylvania
ention the words “life vest” to most people you meet, and
ou may conjure up images of a bright orange buoyancy
evice that you should put on a child when going for a boat
ide on a lake. Others may associate these words with the
ellow inflatable device found somewhere under your seat
n an airplane. Although the flight attendants have told you
bout it many times, you are still not exactly sure how and
hen to operate one. Mention these words to many cardi-
logists these days, and you are talking about a wearable
efibrillator that may be prescribed for your patient with a
ardiomyopathy while he or she waits for a permanent
mplantable cardioverter-defibrillator (ICD) to be im-
lanted or reimplanted.
See page 194
The wearable cardioverter-defibrillator (WCD) is pro-
uced by a single manufacturer, ZOLL Lifecor Corp.,
ittsburgh, Pennsylvania, and received U.S. Food and Drug
dministration approval in 2002. This device is currently
eing marketed around the world for 4 types of patients:
) patients with a left ventricular ejection fraction 35%
aiting for the reimbursement-mandated 30- to 90-day
indow from initial diagnosis or revascularization to elapse
efore ICD implantation; 2) patients who do not currently
eet ICD implantation criteria due to New York Heart
ssociation functional class IV heart failure; 3) patients who
eet ICD implantation criteria but whose condition delays
r prohibits implantation, usually coincident infection; and
) patients who have undergone ICD explantation, usually
or infection, who are receiving a course of antibiotics or
ther treatment before implantation of a new ICD. Until
ecently, data regarding the incidence of sudden death and
he utility of a wearable defibrillator for patients in these
pecific scenarios were scant. Also, patient compliance with
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merican College of Cardiology.a
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atients in clinical studies tend to be more compliant, but
ould “real-world” patients prescribed these devices actually
se them long enough to receive benefit?
The paper by Chung et al. (1) in this issue of the Journal
eports the outcomes in 3,500 patients from the manu-
acturer’s database who wore this device between August
002 and December 2006. They compared the survival rates
f these patients with those of patients undergoing first
CD implantation at the Cleveland Clinic between August
996 and 2004. Like many reviews of large databases not
ntended for rigorous academic scrutiny, this paper is
lagued by missing information regarding patient demo-
raphics and indications for these devices. Mortality was not
onfirmed by personal contact of study coordinators, but
nstead taken from the Social Security Death Index. Yet, the
aper does manage to provide important and unequivocal
ata.
First, the paper documents that these patients did,
ndeed, wear these devices. The 3,569 patients wore the
CDs for a total of 143,643 days for a mean use of 50
ays and a range of 1 to 1,590 days. The investigators
alculated that patients wore these devices for a mean of
lmost 20 h/day. Daily use was confirmed in 90% of
atients, and 15% of patients stopped wearing the WCD
rematurely because of comfort issues or adverse reactions.
Second, the paper documents that the WCD successfully
reats tachyarrhythmias. During the time that these devices
ere worn, 80 sustained ventricular tachycardia (VT)/
entricular fibrillation (VF) events were recorded in 59
atients (1.7% of the study cohort). The first shock was
uccessful in 79 of 80 patients. The only patient who failed
WCD shock had hemodynamically tolerated VT that also
ailed several external shocks delivered by emergency med-
cal service workers in the ambulance and hospital staff
embers in the emergency department. His VT was later
erminated pharmacologically. Although the shocks were
ffective, 8 of these patients died, all of recurrent arrhyth-
ias: 4 after recovering consciousness and the arrival of
rofessional medical care, 1 whose spouse prevented a
econd WCD shock, 2 due to electrocardiogram signal
isruption presumably after a fall, and 1 who failed detec-
ion due to a pacemaker operating in a unipolar mode.
lthough the success rates for treating VT and VF were
xcellent, not all cardiac arrests were secondary to tachyar-
hythmias. Twenty-three asystolic events were recorded,
esulting in 17 deaths, and 3 pulseless electrical activity
vents resulting in death were confirmed by medical per-
onnel at the site. Unlike implanted defibrillators, the WCD
annot deliver antibradycardia pacing during these events
ut can only alert bystanders to call for an ambulance.
Third, the paper allays concerns of inappropriate shocks
nd device pro-arrhythmia. Once the device meets its
rescribed criteria for detecting a tachyarrhythmia, it sets off
series of vibratory and auditory alerts. Because patients can
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July 13, 2010:204–5 The WCD: Lifesaving Attire or “Fashion Faux Pas?”revent a shock by holding the response button, inappro-
riate sensing rarely resulted in a shock. Only 67 episodes of
nappropriate ICD discharges were logged in these 3,569
atients during 4,788 months of use. These results are not
issimilar to those of inappropriate shocks from ICDs (2).
Finally, and I believe most importantly, this paper gives
ome guidance regarding which patients may benefit most
rom using this technology. Although by no means a
andomized study, this analysis meticulously classified most
atients according to common indications for prescription
f this device. The authors divided the population into 2
roups: those who received the WCD for traditional ICD
mplantation criteria and those who received it for nontra-
itional ICD indications. The traditional group comprised
types of patients: 1) those who recently had an ICD
xplanted; 2) those with an episode of VT/VF awaiting
CD implantation; 3) those with a long-standing cardiomy-
pathy and left ventricular ejection fraction of 35%; and
) those with a genetic predisposition to sudden cardiac
eath. Nontraditional indications mainly included 2 groups
f patients: 1) those with a left ventricular ejection fraction
35% but who had only recently been diagnosed or had a
ecent myocardial infarction or recent coronary bypass
urgery; and 2) those with a recent myocardial infarction
nd an ejection fraction 35%.
Although the 2 groups (traditional vs. nontraditional
CD indications) were very similar in patient numbers,
ppropriate WCD shocks were much more common (58 vs.
2) in the traditional indication group. When followed for
ong-term survival using the Social Security Death Index,
he traditional group had a higher mortality, confirming
hat they are indeed a higher risk population. Almost 40%
f the patients in the entire study for whom the WCD was
rescribed were either awaiting reimplantation of an ICD
fter explantation or had experienced VT/VF and were
waiting improvement in their comorbidities before initial
CD implantation. The WCD appropriately shocked 39 of
hese 1,077 patients (3.6% of this cohort) for 58 separate
pisodes of VT/VF. Of these 39 patients, 36 survived.
learly, this device can be lifesaving attire for these patients
ho have traditional indications for an ICD but must wait
or an infection to clear or other comorbidities to resolve.
Yet, not all of the benefits of the WCD were realized in
he traditional ICD group. Although the VALIANT (Val-
artan in Acute Myocardial Infarction) study demonstrated
high incidence of sudden cardiac death in patients with
arly post-myocardial infarction with left ventricular ejec-
ion fractions 35% (3), the DINAMIT (Defibrillator in
cute Myocardial Infarction Trial) failed to show a benefit
f early ICD implantation in this population, possibly
K
decause of the high incidence of heart failure deaths or
ossibly because ejection fractions may improve, leaving
atients with a low risk of ventricular tachyarrhythmia (4).
his group of patients, however, is covered by Medicare to
btain WCDs, and the device did appear to be beneficial for
embers of this cohort in the study. Ten of these 341
atients with early post-infarct ischemic cardiomyopathies
2.9%) received appropriate WCD shocks for 12 separate
pisodes of VT/VF; 8 of the 10 survived.
Some patient groups did not receive a great deal of benefit
rom the WCD. None of the 104 patients with recent
yocardial infarction and an ejection fraction 35% re-
eived an appropriate shock from their WCD. Primary
revention with an ICD is not indicated in this patient
opulation, and I believe that the WCD should not be
rescribed in this scenario. Patients with a recent diagnosis
f nonischemic cardiomyopathy accounted for 20% of the
tudy population, but only 4 patients (0.7%) received ap-
ropriate shocks, 1 of whom later died. Patients who were
arly post-coronary artery bypass graft had an appropriate
hock rate of 0.8%, and only 1 of those 2 patients survived.
believe that the WCD should not be routinely prescribed
or these patients either.
In conclusion, the WCD is a technology that can save
ives if prescribed for the correct patients. It has a high
egree of success in treating ventricular tachyarrhythmias
nd does not appear to be very cumbersome for patient use.
ot prescribing this lifesaving attire to your high-risk
atient awaiting ICD implantation or reimplantation is the
eal faux pas.
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